Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors

Background A phase I study to assess the maximum tolerated dose (MTD) of a short course of afatinib in combination with docetaxel for the treatment of solid tumors. Methods Patients with advanced solid malignancies received docetaxel 75 mg/m(2) intravenously on day 1 and oral afatinib once daily on...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Awada, A. H., Dumez, H., Hendlisz, A., Wolter, P., Besse-Hammer, T., Uttenreuther-Fischer, M., Stopfer, P., Fleischer, F., Piccart, M., Schöffski, P.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer US 2012
Aiheet:
Phase I Studies
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3644400/
https://ncbi.nlm.nih.gov/pubmed/23161334
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-012-9880-0
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia